

December 20, 2023



PDRadiopharma Inc.

## Approval of Insurance Coverage of AMYViD<sup>®</sup>, a PET Imaging Agent for Detecting Beta Amyloid

*\*This release is an English translation of “アミロイドPET 検査用イメージング剤「アミヴィット®静注」の保険適用に関するお知らせ”, with a priority given to Japanese for content and interpretation. The indication is specifically for Japan only and not for other countries.*

TOKYO, JAPAN – December 20, 2023 - PDRadiopharma Inc. (President: Susumu Tanahashi, Headquarters: Chuo-ku, Tokyo, Japan) today announced that the company has received approval for insurance coverage of AMYViD<sup>®</sup> Injection (generic name: florbetapir (<sup>18</sup>F)) in Japan.

- Product name: AMYViD<sup>®</sup> Injection
- Indication: Visualization of beta amyloid plaques in the brain of patients with mild cognitive impairment or suspected to have dementia due to Alzheimer's disease
- Insurance coverage start date: December 20, 2023

In conjunction with the insurance coverage of lecanemab to treat dementia in Japan, the amyloid PET imaging procedure will also be covered, and amyloid PET imaging agents including AMYViD will be added to the list of "Drugs for Use Without Reimbursement Price<sup>\*2</sup>". As a result, the use of amyloid PET imaging agents to assess eligibility for treatment with lecanemab will be reimbursed by National Health Insurance.

With the number of dementia patients rapidly increasing due to an aging population, the medical treatment of dementia has entered a new era with the emergence of novel therapeutics. PDRadiopharma is committed to contribute to the advancement of dementia treatment by providing innovative diagnostics and will continue to support patients suffering from dementia and their families.

\*1 PET: Positron Emission Tomography

\*2 Therapeutics that are not listed in Japanese National Health Insurance (NHI) Drug Price Standards, but the cost of the drug is included in the reimbursement score

### **About AMYViD<sup>®</sup> Injection (generic name: florbetapir(<sup>18</sup>F))**

AMYViD<sup>®</sup> Injection obtained marketing authorization in December 2016 as the first flexible-dose<sup>TM</sup> formulation which differs from

conventional radiopharmaceuticals in Japan. The indication for patients with suspected mild cognitive impairment due to Alzheimer's disease was expanded on August 31, 2023. AMYViD® is a registered trademark of Avid Radiopharmaceuticals, Inc.

#### **About PDRadiopharma**

PDRadiopharma has been providing high-quality radiopharmaceuticals since it started its business in 1968. Our vision is to shine the lives through innovative diagnostics and therapeutics using radiopharmaceuticals. Currently, we domestically market 22 SPECT diagnostics, 2 PET diagnostics, and 8 therapeutic drugs (3 product categories). For more information, please visit <https://www.pdradiopharma.com/>

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: [info@peptidream.com](mailto:info@peptidream.com)